We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock
SEEL

Delisted

SEEL was delisted on the 15th of October, 2024.

Back to rankings

67 hedge funds and large institutions have $7M invested in Seelos Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 20 increasing their positions, 9 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

762% more call options, than puts

Call options by funds: $181K | Put options by funds: $21K

122% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 9

6% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 16

1% less funds holding

Funds holding: 68 → 67 (-1)

74% less capital invested

Capital invested by funds: $27.1M → $7M (-$20.1M)

Holders
67
Holders Change
-1
Holders Change %
-1.47%
% of All Funds
1.06%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
15
Increased
20
Reduced
9
Closed
16
Calls
$181K
Puts
$21K
Net Calls
+$160K
Net Calls Change
-$460K

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$13.2M
2
WE
Wealth Effects
Massachusetts
+$2.21M
3
GJL
Gendell Jeffrey L
+$1.76M
4
Osaic Holdings
Osaic Holdings
Arizona
+$707K
5
MWM
Modera Wealth Management
New Jersey
+$394K

Top Sellers

Rank Fund Capital Flow
1
UIC
Uniplan Investment Counsel
Wisconsin
-$1.34M
2
MCM
MAI Capital Management
Ohio
-$935K
3
EWA
EP Wealth Advisors
California
-$206K
4
Millennium Management
Millennium Management
New York
-$184K
5
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
-$141K
Name Holding Trade Value Shares
Change 		Change in
Stake
WP
26
WealthPLAN Partners
Nebraska
$10.4K +$8.57K +2 +15%
Mariner
27
Mariner
Kansas
$9.79K – – –
Bank of New York Mellon
28
Bank of New York Mellon
New York
$9.72K – – –
Jane Street
29
Jane Street
New York
$8K +$47.2K +11 New
SOW
30
State of Wyoming
Wyoming
$7.37K +$4.29K +1 +11%
RCG
31
Resource Consulting Group
Florida
$6.98K +$42.9K +10 New
Prudential Financial
32
Prudential Financial
New Jersey
$6.59K +$38.6K +9 New
HSBC Holdings
33
HSBC Holdings
United Kingdom
$6.46K – – –
CHA
34
Carmichael Hill & Associates
Maryland
$5.7K +$12.9K +3 +60%
Wells Fargo
35
Wells Fargo
California
$5.69K – – –
JP Morgan Chase
36
JP Morgan Chase
New York
$5.61K +$8.57K +2 +33%
Envestnet Asset Management
37
Envestnet Asset Management
Illinois
$5.52K +$34.3K +8 New
CA
38
Crewe Advisors
Utah
$5.11K – – –
SG Americas Securities
39
SG Americas Securities
New York
$5K -$4.29K -1 -11%
Commonwealth Equity Services
40
Commonwealth Equity Services
Massachusetts
$5K – – –
FHC
41
First Heartland Consultants
Missouri
$5K – – –
PCIA
42
Prime Capital Investment Advisors
Kansas
$4.32K +$25.7K +6 New
DFG
43
Delta Financial Group
New Jersey
$4K – – –
SFG
44
Sovereign Financial Group
Connecticut
$3.68K -$47.2K -11 -69%
CGA
45
Crescent Grove Advisors
Illinois
$3.68K +$21.4K +5 New
MCM
46
MAI Capital Management
Ohio
$3.07K -$935K -218 -98%
Lazard Asset Management
47
Lazard Asset Management
New York
$3K – – –
VFA
48
Valeo Financial Advisors
Indiana
$2.73K – – –
IWC
49
Integrated Wealth Concepts
Massachusetts
$2.69K – – –
TSS
50
Two Sigma Securities
New York
$2.67K -$17.1K -4 -50%
1
2
3 4

SEEL Hedge Fund Activity: Q3 2023 in Review

67 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q3 2023, worth a combined $7M — down 74% from $27.1M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of SEEL and 15 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 20 added.

The largest buyer was Sabby Management, opening a new position worth an estimated $13.2M. The largest seller was Uniplan Investment Counsel, exiting entirely with an estimated $1.34M sold.

  • 67 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q3 2023, down from 68 in Q2 2023.
  • Funds reported $7M of Seelos Therapeutics, Inc. Common Stock stock for Q3 2023, down 74% quarter-over-quarter.
  • 15 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q3 2023 and 16 closed out, a net change of -1 holder.
  • The largest Seelos Therapeutics, Inc. Common Stock buyer in Q3 2023 was Sabby Management, an estimated $13.2M added.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q3 2023 was Uniplan Investment Counsel, an estimated $1.34M sold.

Based on aggregated 13F filings for Q3 2023.